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Results Inhibition of CYP3a4 by ketoconazole increased 
midostaurin exposure more than tenfold, and induction of 
CYP3a4 by rifampicin decreased midostaurin exposure 
by more than tenfold. Midostaurin did not appreciably 
affect the concentrations of midazolam or its metabolite, 
1′-hydroxymidazolam, at single or multiple doses.
Conclusion the pharmacokinetics of midostaurin and 
its metabolites was affected substantially by ketoconazole 
and rifampicin, suggesting that midostaurin is a sensitive 
CYP3a4 substrate. Midostaurin did not appear to inhibit or 
induce CYP3a4 in vivo.
Keywords FMS-related tyrosine kinase 3 (Flt3) 
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Pharmacokinetics · rifampicin
Introduction
Midostaurin, an orally bioavailable staurosporine ana-
logue, is a multitargeted tyrosine kinase inhibitor that tar-
gets FMS-related tyrosine kinase 3 (Flt3), wild-type and 
mutant KIt, platelet-derived growth factor receptor β, 
and other receptors [1–3]. Midostaurin is metabolized in 
humans primarily via cytochrome P450 3a4 (CYP3a4) 
into two major pharmacologically active circulating metab-
olites, CgP62221 (via O-demethylation) and CgP52421 
(via 7-hydroxylation) [4–6]. In vitro studies have shown 
that midostaurin, CgP62221, and CgP52421 inhibit 
mutant Flt3 at low nanomolar concentrations, with half-
maximal inhibitory concentrations (IC50) of 10–36, 26, and 
584 nM, respectively [3, 4]. the apparent elimination half-
life (t1/2) of CgP52421 is long, ranging from 16 to 31 days 
[5, 6]; thus, CgP52421 may contribute to sustained in vivo 
activity.
Abstract 
Purpose Midostaurin (PKC412), a multitargeted tyrosine 
kinase inhibitor that targets FMS-related tyrosine kinase 3 
and KIt, is in clinical trials for the treatment for acute mye-
loid leukemia and advanced systemic mastocytosis. In vitro 
studies showed that midostaurin is predominantly metabo-
lized by cytochrome P450 3a4 (CYP3a4) and that midos-
taurin inhibits and/or induces the same enzyme. Here, we 
address the clinical relevance of CYP3a4-related drug–
drug interactions with midostaurin as either a “victim” or 
“perpetrator.”
Methods three phase I studies in healthy volunteers 
evaluated the effects of a CYP3a4 inhibitor (ketoconazole 
400 mg daily for 10 days) or CYP3a4 inducer (rifampicin 
600 mg daily for 14 days) on concentrations of midos-
taurin and its metabolites following a single 50-mg dose 
of midostaurin and the effects of midostaurin as a single 
dose (100 mg) and multiple doses (50 mg twice daily) on 
midazolam (a sensitive CYP3a4 probe) concentration. 
the plasma concentrations of midostaurin and its 2 active 
metabolites, CgP62221 and CgP52421, were determined 
using a sensitive liquid chromatography/tandem mass spec-
trometry method.
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Mutations in FLT3 and KIT have been shown to play a 
role in the development of malignancies such as acute mye-
loid leukemia (aMl) and advanced systemic mastocytosis 
(aSM) [7–9]. approximately 30 % of patients with aMl 
have FLT3 mutations that lead to constitutive activation 
[1]. Midostaurin has demonstrated clinical activity as a sin-
gle agent or in combination with chemotherapy in patients 
with aMl [10, 11] and is currently under investigation in a 
phase III clinical trial in patients with newly diagnosed aMl 
who have a mutation in FLT3 [12]. Most patients with aSM 
(≈80 %) have gain-of-function mutations in KIT, particu-
larly the D816V mutation [13]. a phase II investigator-initi-
ated study of midostaurin 100 mg twice daily in 26 patients 
with aSM demonstrated a response rate of 69 % accord-
ing to Valent criteria [14], including 10 major responses (6 
incomplete remissions and 4 pure clinical responses); 5 good 
partial responses; and 3 minor partial responses [15]. Strong 
responses were observed in patients with the KIT D816V 
mutation, the majority of whom achieved a major response 
[15]. Furthermore, a 60 % overall response rate (53 % major 
response) was reported in the stage 1 analysis of an ongoing 
global phase II study of midostaurin in patients with aSM 
or mast cell leukemia with or without an associated clonal 
hematologic non-mast cell lineage disease, the majority of 
whom (70 %) were KIT D816V/Y-positive [16].
Previous studies have evaluated the pharmacokinetics 
(PK) of midostaurin in patients with aMl [11, 17] and dia-
betes [6]. these studies showed that midostaurin is rapidly 
absorbed after oral administration, with peak plasma con-
centrations observed at 1–3 h postdose. a separate study in 
healthy volunteers found that the mean apparent volume of 
distribution of midostaurin (111 l) was higher than that of 
total body water (42 l), indicating a high tissue distribution 
[18]. the maximal concentration (Cmax) and area under the 
concentration curve (aUC) increased proportionally with 
dose following single-dose administration of midostaurin 
between 25- and 50-mg doses but under proportionally 
between 50- and 100-mg doses [6].
Upon daily oral dosing, midostaurin concentrations 
accumulated in a time-linear manner in the first 3–6 days. 
thereafter, the PK becomes time-dependent; the plasma 
concentrations of midostaurin decreased substantially 
between days 6 and 14 and reached a new plateau after 
2–3 weeks of daily dosing [18]. this concentration drop 
over time necessitates twice-daily administration of midos-
taurin to maintain long-term target drug levels. the con-
centrations of CgP62221 metabolite showed a similar time 
profile as the parent drug midostaurin. In contrast, plasma 
levels of the metabolite CgP52421 rose over treatment 
cycles, as expected by its long half-life of >1 month [5, 6].
the long plasma half-lives of midostaurin and its metab-
olites could be due to their specific and strong binding to 
the human serum protein α1-acid glycoprotein (aag). 
Midostaurin, CgP62221, and CgP52421 are 88–98 % 
bound to aag [19], resulting in free midostaurin concen-
trations of approximately 0.02–1 μM [18]. Fecal excretion 
is the major pathway for the elimination of midostaurin, 
CgP62221, and CgP52421 [18].
given the prominent role of CYP3a4 in midostau-
rin metabolism, drug–drug interactions (DDIs) that affect 
the exposure of midostaurin and its metabolites may occur 
when midostaurin is co-administered with potent CYP3a4 
inhibitors or inducers. Furthermore, midostaurin and its 
major metabolites inhibit CYP3a4/5 activity in vitro (mida-
zolam 1′-hydroxylation, IC50 = 1.5 μM for midostaurin and 
CgP52421 and IC50 <1 μM for CgP62221) [18] and activate 
the pregnane X receptor at concentrations of 1–50 μmol/l in 
a CYP3a4 reporter gene assay [6]. therefore, it is possible 
that midostaurin and/or its metabolites may affect the meta-
bolic clearance of comedications metabolized by CYP3a4.
to address the clinical relevance of CYP3a4-related 
DDIs at clinically relevant doses, a series of studies was 
performed in healthy volunteers. Herein, we describe 
the results of these studies that evaluated the effects of a 
CYP3a4 inhibitor (ketoconazole) or CYP3a4 inducer 
(rifampicin) on concentrations of midostaurin and its 
metabolites and the effects of midostaurin on the PK of 
midazolam (a sensitive CYP3a4 probe).
Methods
Participants
all studies enrolled healthy volunteers. eligible individuals 
were aged 18–55 years, weighed 50–90 kg, had a body mass 
index of 18–29.9 kg/m2 (upper limit of 30 kg/m2 for the 
ketoconazole study), and had normal blood pressure. Volun-
teers were excluded from participation if they tested positive 
for HIV, hepatitis B, or hepatitis C or if they had an abnor-
mal electrocardiogram, a history of myocardial infarction, 
or a family medical history of long Qt interval syndrome. 
Women currently pregnant or breast-feeding were excluded, 
as were individuals who had used any prescription medica-
tion within 14 days or over-the-counter medication in the 
past 7 days. additionally, participants had to be willing to 
abstain from sexual intercourse or use an approved form of 
contraception while on study. additional inclusion/exclu-
sion criteria are included in Supplementary table 1.
Study designs and objectives
Midostaurin PK when administered with ketoconazole
In this single-center, open-label, randomized, parallel-
group phase I study, healthy volunteers were randomized 
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to receive either ketoconazole 400 mg or placebo daily 
from day 1 to day 10; in addition, all participants received 
midostaurin 50 mg once on day 6 (table 1). according 
to the US Food and Drug administration, ketoconazole 
400 mg once daily is the recommended dose to evaluate 
DDIs involving CYP3a4 inhibition [20].
Table 1  Study designs
Study Day
Screening
(day −14 to −2)
Baseline
(day −1) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Midostaurin PK when administered with ketoconazole (a CYP3A4 inhibitor)
Placebo + 
midostaurin (n = 20)
Placebo daily
Midostaurin 50 mg daily
Ketoconazole + 
midostaurin (n = 27)
Ketoconazole 400 mg daily
Midostaurin 50 mg daily
PK assessments
Midostaurin level (plasma) a a a a a a
Ketoconazole level (plasma) b b b
Midostaurin PK when administered with rifampicin (a CYP3A4 inducer)
Placebo + 
midostaurin (n = 22)
Placebo daily
Midostaurin 50 mg daily
Rifampicin + 
midostaurin (n = 25)
Rifampicin 600 mg daily
Midostaurin 50 mg daily
PK assessments
Midostaurin level (plasma) a a a a a a a
Rifampicin level (plasma) c c c
4β-HC level (plasma) and 
6β-HC/cortisol ratio (urine)
d d d d
Midazolam PK when administered with midostaurin (a CYP3A4 probe)
Midazolam + 
midostaurin (n = 20)
Midazolam 4 mg daily
Midostaurin 100 mg daily
Midostaurin 50 mg twice daily
PK assessments
Midostaurin level (plasma) e e e e e
Midazolam level (plasma) f f f
4β-HC level (plasma) and 
6β-HC/cortisol ratio (urine) 
g g g g g g
Black highlight indicates midostaurin. Medium gray highlight indicates CYP3a4 inhibitor, inducer, or probe. light gray highlight indicates pla-
cebo. Double vertical lines indicate the end of a given study
4β-HC 4β-hydroxycholesterol, 6β-HC 6β-hydroxycortisol, CYP3A4 cytochrome P450 3a4, PK pharmacokinetics
a
 Blood samples for the determination of midostaurin PK were collected predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h 
after midostaurin dosing on day 6 (ketoconazole study) and day 9 (rifampicin study). In the rifampicin study, an additional sample was taken at 
144 h after midostaurin dosing on day 9
b
 On days 4–6, blood samples were collected before the morning dose to measure ketoconazole levels
c
 On days 6, 9, and 14, blood samples were collected for rifampicin assessment before the evening rifampicin dose
d
 On days 1 (baseline), 9 (before midostaurin treatment), 11, and 15, levels of 4β-HC in plasma and the ratio of 6β-HC/cortisol in urine were 
assessed
e
 Blood samples for PK determination of midostaurin and its metabolites (CgP62221 and CgP52421) were taken before the morning dose of 
midostaurin on days 4–6 and before midazolam administration on days 7 and 8
f
 Blood samples for the determination of midazolam PK were collected before dose and at 0.25, 0.5, 1, 1.5, 1.75, 2, 3, 4, 6, 8, and 10 h after 
midazolam dosing on days 1, 3, and 8
g
 Blood samples and urine samples were taken on days 1, 3, 6, 7, 8, and 9 to measure 4β-HC in plasma and the ratio of 6β-HC/cortisol in urine, 
respectively
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the primary objective of this study was to investigate 
the effect of ketoconazole on the PK of a single oral dose 
of midostaurin in healthy volunteers. the secondary objec-
tive was to assess the safety and tolerability of a single 
dose of midostaurin given alone or in combination with 
ketoconazole in healthy volunteers. all randomized partici-
pants were included in the population evaluated for safety, 
whereas the PK population only included individuals who 
received all planned doses of the study drug, had evaluable 
PK profiles, and did not vomit within 4 h after midostau-
rin administration. adverse events (aes) were recorded 
during the study and up to 1 month (28 days) after the end 
of study. Volunteers remained at the clinic until aes were 
common toxicity criteria (CtC) grade ≤1. Blood samples 
(4 ml/sample) for the determination of midostaurin PK 
and ketoconazole levels were collected predose and at vari-
ous times after midostaurin dosing on day 6 (table 1).
Midostaurin PK when administered with rifampicin
In this open-label, randomized, parallel-group phase I 
study, healthy volunteers were randomized to receive either 
rifampicin 600 mg or placebo daily from day 1 to day 14; 
all participants received midostaurin 50 mg once on day 9 
(table 1). the primary objective of this study was to inves-
tigate the effect of co-administration of rifampicin on the 
PK of a single oral dose of midostaurin in healthy volun-
teers. the secondary objective was to investigate the safety 
and tolerability of midostaurin alone and in combination 
with rifampicin. the PK and safety populations and safety 
assessments used the same definitions as those in the keto-
conazole study.
Blood samples were collected at various times to assess 
midostaurin PK and rifampicin levels (table 1). In addition, 
on days 1 (baseline), 9 (before midostaurin treatment), 11, 
and 15, levels of 4β-hydroxycholesterol in plasma and the 
6β-hydroxycortisol/cortisol ratio in urine were assessed. 
these endogenous molecules served as exploratory bio-
markers for CYP3a4 activity in vivo [21, 22].
Midazolam PK when administered with midostaurin
In this open-label, single-arm phase I study, healthy volun-
teers were administered the following treatment regimen: 
on day 1, participants received a solution of midazolam 
4 mg with a standard breakfast; day 2 was a rest day dur-
ing which no treatment was administered; on day 3, par-
ticipants received midostaurin 100 mg plus a solution of 
midazolam 4 mg with a standard breakfast (table 1). On 
days 4–6, participants received midostaurin 50 mg twice 
daily with a standard breakfast; day 7 was a rest day with 
no treatment administered; on day 8, participants received a 
solution of midazolam 4 mg with a standard breakfast. the 
drug holiday on day 7 was added to minimize the inhibitory 
effect of midostaurin on CYP3a4 prior to midazolam dos-
ing on day 8. Such a holiday is feasible without affecting 
enzyme induction because of the long half-lives of midos-
taurin and its metabolites [23] and the long degradation 
half-life of CYP3a4 (approximately 3 days) [24].
the primary objective of this study was to investigate 
the potential effect of midostaurin as “perpetrator” on the 
PK of midazolam as an inhibitor on day 3 and a potential 
inducer on day 8. Both inhibition and induction of mida-
zolam clearance were investigated. the secondary objective 
was to investigate the safety and tolerability of concomitant 
administration of midazolam and midostaurin. all volun-
teers were included in the population evaluated for safety, 
whereas the PK population only included individuals who 
took all scheduled doses of midostaurin and midazolam 
without vomiting within 4 h after dosing.
Blood samples were collected at various time points to 
assess midazolam PK as well as levels of midostaurin and 
its metabolites (table 1). Similarly, blood and urine samples 
were taken on days 1, 3, 6, 7, 8, and 9 to measure the levels of 
4β-hydroxycholesterol in plasma and the 6β-hydroxycortisol/
cortisol ratio in urine, markers of CYP3a4 activity.
PK and statistical data analyses
DDI with ketoconazole
the PK parameters of midostaurin and its metabolites 
[Cmax, time to reach maximal concentration (tmax), aUC0–last, 
aUCinf, and t1/2] were derived using noncompartmental 
methods with the aid of Winnonlin 5.2 software (Pharsight 
Corp, St louis, MO, USa). Because of the long appar-
ent elimination t1/2 of CgP52421, it was not possible with 
the given sampling schedule to reliably estimate aUC0–inf 
and t1/2 values for this analyte. Following log transforma-
tion, aUC0–last and Cmax were analyzed separately using an 
analysis of variance (anOVa) model including a term for 
treatment (“ketoconazole + midostaurin” as test and “pla-
cebo + midostaurin” as reference). a point estimate and 
the corresponding 90 % CI for the treatment effect were 
calculated for the test treatment compared with the refer-
ence. these were anti-logged to obtain the point estimate 
and the 90 % CI for the geometric mean ratio (gMr) on 
the untransformed scale. aUC0–inf was also analyzed for 
midostaurin and its active metabolite CgP62221 using the 
same method. all anOVas were performed using SaS 
software (SaS Institute Inc., Cary, nC, USa).
DDI with rifampicin
the PK parameters of midostaurin and its metabolites 
(Cmax, tmax, aUC0–last, aUCinf, t1/2, and Cl/F) were derived 
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using noncompartmental methods with the aid of Win-
nonlin 5.2. as in the ketoconazole study, the sampling 
schedule was not consistent with obtaining good estimates 
of the apparent terminal t1/2 and consequently aUCinf for 
CgP52421. Following log transformation, the primary 
variables were analyzed separately using an anOVa model 
including a term for treatment (“rifampicin + midostaurin” 
as test and “midostaurin + placebo” as reference). a point 
estimate and the corresponding 90 % CI for the treatment 
effect (test vs reference) were calculated. these were anti-
logged to obtain the gMr and respective 90 % CI. the 
tmax for midostaurin (and its metabolites) was compared 
between the test and reference treatments by comparing the 
median, minimum, and maximum values in the two treat-
ment conditions. the median difference was estimated with 
the Hodges–lehmann estimator and its respective exact 
two-sided 90 % CI. all formal comparative statistical anal-
yses were performed using SaS software.
DDI with midazolam
the PK parameters of midazolam and its metabolites (Cmax, 
tmax, aUC0–last, aUCinf, and t1/2) were derived using a non-
compartmental method with the aid of Winnonlin 5.2. In 
this study, the reference treatment was midazolam adminis-
tered alone on day 1, and this was compared with two test 
treatments defined as (1) midazolam with midostaurin on 
day 3 (to test for inhibition of CYP3a4 by midostaurin) 
and (2) midazolam alone on day 8 (to test for induction of 
CYP3a4 by midostaurin). Following log transformation, 
the primary PK parameters were analyzed using a linear, 
mixed-effects model using the term of treatment as a fixed 
factor (reference, test 1, test 2) and subject as a random fac-
tor. a point estimate and the corresponding 90 % CI for the 
difference in test 1 versus reference and the difference in 
test 2 versus reference were derived from the respective 
contrasts of the model estimates and anti-logged to obtain 
the gMr and respective 90 % CI.
Bioanalytical methods
the concentrations of unchanged midostaurin, CgP52421, 
and CgP62221 in the plasma were determined using a 
validated liquid chromatography–tandem mass spectrom-
etry (lC–MS/MS) assay with a lower limit of quantitation 
(llOQ) of 10 ng/ml (novartis SaS France bioanalyt-
ics and SgS, Cephac europe, SaS). the concentration 
of ketoconazole in plasma was assessed using a validated 
lC–MS/MS assay with an llOQ of 50.0 ng/ml (WuXi 
Pharmatech Co, ltd, China). the concentration of rifampicin 
in plasma was measured using a validated lC–MS/MS assay 
with an llOQ of 5.0 ng/ml (SgS, Cephac europe, SaS). 
Plasma concentrations of midazolam and its metabolite 
1′-hydroxymidazolam, which is generated by CYP3a4 
and CYP3a5 in humans, were measured using a vali-
dated lC–MS/MS assay with an llOQ of ≈0.100 ng/ml 
(SgS, Cephac europe, SaS). the plasma concentration of 
4β-hydroxycholesterol was measured using a validated lC–
MS/MS assay with an llOQ of 3.0 ng/ml (SgS, Cephac 
europe, SaS). the concentrations of 6β-hydroxycortisol 
and cortisol in urine were determined using validated 
lC–MS/MS assays with an llOQ of 10.0 ng/ml for 
6β-hydroxycortisol and 1.0 ng/ml for cortisol. the ratio of 
6β-hydroxycortisol to cortisol was subsequently calculated 
(SgS, Cephac europe, SaS). See Supplementary table 2 for 
detailed bioanalytical methods for all 3 studies.
ethics
all studies were conducted in accordance with the Dec-
laration of Helsinki, and all volunteers provided written 
informed consent according to institutional guidelines. all 
studies were conducted at the early Phase Clinical Unit of 
PareXel International gmbH in Berlin, germany. all 
study protocols were reviewed and approved by the State 
Office of Health and Social affairs ethics Committee of 
Berlin (landesamt für gesundheitund Soziales ethik-Kom-
mission des landes Berlin) for PareXel International 
gmbH (DDI with ketoconazole, eudraCt 2008-003038-
39; DDI with rifampicin, eudraCt 2009-009895-11; DDI 
with midazolam, eudraCt 2009-009870-29).
Results
Demographics of healthy volunteers
these 3 studies enrolled 114 healthy volunteers. In all 3 
studies, there were 3 populations: the randomized set, the 
safety set, and the PK set. the randomized set included all 
participants who were randomized. the safety set included 
all participants who received at least 1 dose of study drug. 
the PK set included all participants who received all 
scheduled doses of study drug and had evaluable PK data; 
participants who vomited within 4 h after receiving study 
drug were excluded from the PK set.
the study of midostaurin and ketoconazole enrolled 47 
healthy volunteers with a median age of 44 years (range 
20–55 years); 62 % of participants were male. twenty par-
ticipants were randomized to receive midostaurin alone, 
and 27 participants were randomized to receive midostau-
rin plus ketoconazole. all 47 individuals received ≥1 dose 
of study drug and were included in the safety population. 
DDIs were assessed in the PK population, which included 
36 participants who completed all scheduled doses of study 
drug and provided evaluable PK profiles (18 participants 
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each in the midostaurin and midostaurin plus ketoconazole 
arms).
the study of midostaurin and rifampicin enrolled 47 
healthy volunteers with a median age of 43 years (range 
19–53 years); 60 % of volunteers were male. twenty-two 
participants were randomized to receive midostaurin alone, 
and 25 participants were randomized to receive midos-
taurin plus rifampicin. the safety population included 46 
individuals who received ≥1 dose of study drug. DDIs 
were assessed in the PK population, which included 40 
participants who completed all scheduled doses of study 
drug and provided evaluable PK profiles (20 participants 
each in the midostaurin plus rifampicin and midostaurin 
only arms).
the study of midostaurin and midazolam enrolled 20 
healthy volunteers with a median age of 38 years (range 
21–54 years); 55 % of volunteers were male. all 20 indi-
viduals received ≥1 dose of study drug and were included 
in the safety population. DDIs were assessed in the PK 
population, which included 18 participants who completed 
all scheduled doses of study drug and provided evaluable 
PK profiles. Baseline characteristics were similar across all 
arms of the 3 studies (Supplementary table 3).
PK results
Midostaurin PK when administered with ketoconazole
the effects of the potent CYP3a4 inhibitor ketoconazole 
on midostaurin PK are shown in table 2 and Fig. 1. Fol-
lowing inhibition of CYP3a4 by ketoconazole, the Cmax of 
midostaurin increased by ≈1.8-fold and the aUC increased 
by tenfold compared with placebo. the Cmax of midostau-
rin’s metabolites decreased by twofold with ketoconazole 
compared with placebo. In the presence of ketoconazole, 
the elimination t1/2 of midostaurin and CgP62221 were 
prolonged, indicating that both the formation of this metab-
olite and its subsequent clearance were inhibited. the frac-
tion of midostaurin metabolized by CYP3a4 (FmCYP3a4) 
was 91 %, calculated by the following equation:
  
Midostaurin PK when administered with rifampicin
the effects of the CYP3a4 inducer rifampicin on the 
plasma concentration–time profiles of midostaurin, 
CgP62221, and CgP52421 are shown in table 2 and 
Fig. 2. Co-administration of rifampicin with midostaurin 
notably decreased Cmax and aUC of midostaurin, with an 
increase in the geometric mean of the apparent clearance 
FmCYP3A4 = 1 − AUCinf(without ketoconazole)/AUCinf
(with ketoconazole) = 1 − (19, 762/205, 911) = 0.91.
of midostaurin by 16.9-fold on average. Both metabolites, 
CgP62221 and CgP52421, exhibited the same pattern as 
midostaurin, showing decreases in Cmax and aUC when 
midostaurin was co-administered with rifampicin. Median 














































































































48 72 96 120
48 72 96 120
48 72 96 1202480
Fig. 1  arithmetic means of the plasma concentration–time profiles 
of a midostaurin, b CgP62221, and c CgP52421 after oral admin-
istration of midostaurin 50 mg daily with placebo or ketoconazole 
400 mg daily to healthy volunteers
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1.2-fold for CgP52421 in the midostaurin + placebo arm 
compared with the midostaurin + rifampicin arm. In the 
midostaurin + rifampicin arm, the exposure (aUClast) for 
CgP62221 and CgP52421 decreased by 13.0- and 2.45-
fold, respectively.
to confirm that the decreased exposure of midos-
taurin observed was a result of CYP3a4 induction, 
the levels of 4β-hydroxycholesterol in plasma and the 
6β-hydroxycortisol/cortisol ratio in urine were evaluated. 
Individuals treated with rifampicin are known to have a 
dose-related increase in the level of 4β-hydroxycholesterol, 
with low intraindividual variability [21, 22]. In the 
midostaurin + rifampicin group, geometric mean lev-
els of 4β-hydroxycholesterol increased from day 1 [22.03 
ng/ml; coefficient of variance (CV%), 36.45] to day 9 
(74.35 ng/ml; CV%, 27.17) and continued to increase 
Fig. 2  arithmetic means of 
the plasma concentration–time 
profiles of a midostaurin, b 
CgP62221, and c CgP52421 
after oral administration of 
midostaurin 50 mg daily with 
placebo or rifampicin 600 mg 
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to day 15 (102.70 ng/ml; CV%, 25.54). additionally, 
there was an ≈4.7-fold increase in the geometric mean 
6β-hydroxycortisol/cortisol ratio from day 1 to day 15. 
In contrast, in the midostaurin + placebo group, no nota-
ble change in geometric mean levels or variability of 
4β-hydroxycholesterol occurred (day 1 25.33 ng/ml; CV% 
34.25; day 9 23.38 ng/ml; CV% 34.60; day 15 23.28 ng/ml; 
CV% 36.27), and the 6β-hydroxycortisol/cortisol ratio did 
not increase from day 1 to day 15.
Midazolam PK when administered with midostaurin
the inhibition assessment on day 3 showed that 
co-administration of midostaurin with midazolam 
decreased the Cmax of both midazolam and 1′-hydroxy-
midazolam by an average of 1.2-fold compared with the 
Cmax values for midazolam alone, as administered on day 
1 (table 3; Fig. 3). no change in aUCinf was observed 
for midazolam or 1′-hydroxymidazolam. In the induction 
assessment (midazolam administered alone on day 8 after 
repeated doses of midostaurin), average decreases in Cmax 
of 1.1- and 1.3-fold were observed for midazolam and 
1′-hydroxymidazolam, respectively, compared with the 
Cmax values for midazolam alone, as administered on day 
1. also, average decreases in aUCinf of 1.1- and 1.3-fold 
were observed for midazolam and 1′-hydroxymidazolam, 
respectively. Furthermore, repeated dosing of midostau-
rin was not accompanied by any notable changes in the 
plasma concentrations of 4β-hydroxycholesterol or in the 
6β-hydroxycortisol/cortisol ratio excreted in urine. there-
fore, these results suggest that the parent drug midostaurin 
is neither an inhibitor nor inducer of CYP3a4 in vivo in 
humans.
Safety
In all 3 studies, midostaurin either as single agent or in 
combination was generally well tolerated, and most aes 
resolved rapidly upon discontinuation of study drug. all 
aes are presented in Supplementary table 4.
Midostaurin administered with ketoconazole
a total of 34 participants (72 %) reported 15 aes; nausea 
was the most frequently reported ae (40 %). Of the 15 
aes reported, 8 aes (dry skin, flatulence, abdominal dis-
tension, cough, nasopharyngitis, pharyngolaryngeal pain, 
sleep disorder, and somnolence) occurred only in the keto-
conazole + midostaurin arm, which had the highest expo-
sure to midostaurin. Six aes (nausea, diarrhea, dizziness, 
Table 3  Summary of plasma PK parameters of midazolam and 1′-hydroxymidazolam in healthy volunteers (n = 18) after administration of 
midazolam 4 mg (days 1, 3, and 8) and midostaurin 100 mg (days 3–6)
all study drugs were given orally. all doses were given once daily unless otherwise noted. Participants in the PK population received all sched-
uled doses without vomiting within 4 h after dosing. all randomized participants not in the PK set did not complete all scheduled dosing without 
vomiting within 4 h after dosing
AUC area under the concentration curve, GMR geometric mean ratio, NR not reported, PK pharmacokinetics, tmax time to reach maximal concen-
tration
a
 For tmax, the median is presented under “adjusted geometric mean,” the Hodges–lehmann estimate of median difference is presented under 
“gMr,” and 90 % distribution-free CI is presented under “90 % CI”
b
 gMr for day 3/day 1 comparison
c
 gMr for day 8/day 1 comparison
PK parameter treatmenta Midazolam 1′-Hydroxymidazolam
adjusted  
geometric meana
gMra (90 % CI) adjusted  
geometric meana
gMra (90 % CI)
aUC0–inf (ng h/ml) Midazolam (day 1) 49.69 18.18
Midazolam + midostaurin (day 3) 49.56 1.00 (0.92–1.08)b 18.54 1.02 (0.93–1.12)b
Midazolam (day 8) 46.96 0.95 (0.87–1.02)c 13.74 0.76 (0.69–0.83)c
aUC0–last (ng h/ml) Midazolam (day 1) 43.12 15.91
Midazolam + midostaurin (day 3) 40.21 0.93 (0.88–0.99)b 15.87 1.00 (0.92–1.08)b
Midazolam (day 8) 40.81 0.95 (0.89–1.01)c 12.57 0.79 (0.73–0.85)c
Cmax (ng/ml) Midazolam (day 1) 13.50 5.83
Midazolam + midostaurin (day 3) 11.02 0.82 (0.67–1.00)b 4.76 0.82 (0.63–1.06)b
Midazolam (day 8) 12.25 0.91 (0.74–1.11)c 4.37 0.75 (0.58–0.98)c
tmax (h) Midazolam (day 1) 0.50 0.50
Midazolam + midostaurin (day 3) 0.50 −0.02 (−0.74 to 1.00)b 0.050 0.13 (−0.50 to 1.50)b
Midazolam (day 8) 0.50 0.12 (−0.12 to 0.26)c 0.50 0.01 (−0.23 to 0.26)c
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vomiting, headache, and rhinitis) occurred in both treat-
ment arms, and 1 ae (feeling cold) was reported only 
in the midostaurin + placebo arm. all aes were mild in 
intensity, and all but one (common cold, which was treated 
with ibuprofen) were resolved without additional therapy. 
there were no serious aes, but 7 participants (15 %) dis-
continued the study because of aes (6 vomiting and 1 com-
mon cold).
Midostaurin administered with rifampicin
twenty-five participants (100 %) in the midostau-
rin + rifampicin arm and 13 participants (62 %) in the 
midostaurin arm experienced an ae. In the midostau-
rin + rifampicin arm, the most frequently reported aes 
were chromaturia (96 %; commonly associated with 
rifampicin therapy), nausea (48 %), diarrhea (20 %), and 
headache (20 %). In the midostaurin + placebo arm, the 
most frequently reported aes were nausea [8 (38 %)] and 
diarrhea [7 (33 %)]; 1 individual experienced a nervous 
system ae (headache). In the midostaurin + rifampicin 
arm, 36 % of participants had nervous system aes (head-
ache in 5 individuals, dizziness in 4, and somnolence in 2).
Midazolam administered with midostaurin
twelve of 20 enrolled participants (60 %) in the safety set 
reported aes. the highest incidence of aes (45 %) was 
observed on day 3, when midazolam and midostaurin were 
co-administered. the most frequently reported aes were 
nausea (40 %) and headache (40 %). the majority of the 
aes were of CtC grade 1 (n = 11) or grade 2 (n = 1, nau-
sea) intensity and were transient.
Discussion
the influence of ketoconazole on midostaurin PK was sig-
nificant (FmCYP3a4 = 91 %), as demonstrated by the large 
increase in midostaurin exposure during co-administration 
with ketoconazole. the relative increase of 1.8-fold in Cmax 
and tenfold in aUC indicated that most of this effect was 
due to a decrease in systemic clearance of midostaurin 
rather than an increase in bioavailability. this DDI can be 
classified as strong (greater than fivefold increase) based on 
a proposed interaction classification by the Pharmaceutical 
research and Manufacturers of america for drugs biotrans-
formed via CYP3a4 [25].
as anticipated based on the ketoconazole study, 
CYP3a4 induction with rifampicin had a pronounced 
impact in the opposite direction on midostaurin expo-
sure. When midostaurin was taken with rifampicin, the 
geometric mean of the apparent clearance of midostau-
rin was increased by an average of 16.9-fold compared 
with midostaurin administered alone. the active metabo-
lites CgP62221 and CgP52421 showed a similar pattern. 
Co-administration of midostaurin and rifampicin resulted 
in decreases in the apparent exposures of CgP62221 and 
CgP52421 by 13.0- and 2.45-fold, respectively, com-
pared with midostaurin alone. these results suggest that 
midostaurin as well as its metabolites, CgP62221 and 
CgP52421, are principally cleared from the body through 
metabolism by CYP3a4. Considering the extent of DDI 
with a potent CYP3a4 inducer, co-administration of strong 
or moderate CYP3a4 inducers should be avoided.
Midostaurin, administered as a single dose or in mul-
tiple doses, did not appear to affect the concentrations of 
midazolam or its metabolite 1′-hydroxymidazolam. as a 
result, it could be concluded that midostaurin is neither a 
CYP3a4 inhibitor nor a CYP3a4 inducer in humans at 
current clinically relevant conditions. However, a definitive 
conclusion cannot be made for the midostaurin metabolites 
CgP62221 and CgP52421 because of their low exposure 































































Fig. 3  arithmetic means of the plasma concentration–time profiles 
of a midazolam and b 1′-hydroxymidazolam on day 1 (midazolam 
4 mg, alone), day 3 (midazolam 4 mg + midostaurin 100 mg), and 
day 8 (midazolam 4 mg, alone). all study drugs were administered 
orally. the concentration–time profiles for midazolam + midostaurin 
(day 3) and midazolam (day 8) have been plotted with a slight shift of 
time to enable better viewing of the differences between the treatment 
days
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dosing. Increasing the length of our PK studies was not 
feasible due to safety concerns in healthy volunteers, but 
an ongoing phase II study of midostaurin in patients with 
aSM showed a significant increase in the level of the 
endogenous CYP3a4 biomarker 4-β-hydroxycholesterol 
in plasma following 1–2 months of daily midostaurin dos-
ing. these results in patients with aSM suggest CYP3a4 
induction, probably by the long half-life metabolite 
CgP52421 [18].
In these studies, the administration of midostaurin, either 
alone or in combination, was generally well tolerated by 
healthy volunteers. all aes were grade 1 with the excep-
tion of two grade 2 events (nausea and common cold).
In summary, these studies showed that midostaurin is a 
“victim” but not a “perpetrator” of CYP3a4. the inhibi-
tion or induction potentials for midostaurin metabolites 
CgP62221 and CgP52421 could not be fully character-
ized due to the long half-lives of these two metabolites in 
humans. the results of these studies provide further guid-
ance on the proper use of midostaurin in clinical settings. 
the PK profile of midostaurin, characterized in these and 
other studies, supports its further evaluation in patients 
with aSM and aMl, including the ongoing global phase 
II study of midostaurin in patients with aSM or mast cell 
leukemia with or without an associated clonal hemato-
logic non-mast cell lineage disease [16], and the ongoing 
randomized phase III trial of induction and consolidation 
chemotherapy with midostaurin or placebo in treatment-
naive patients with Flt3-mutated aMl [Cancer and leu-
kemia group B 10603; randomized aMl trial in Flt3 in 
<60-year-olds (ratIFY)] [12].
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